# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001654954-26-003374
**Filing Date:** 2026-4
**Character Count:** 9511
**Document Hash:** 119e2b9a48151e1c620ea99ae076f081
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-003374.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001654954-26-003374

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260409

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 26850724

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

 **FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2026

Commission File Number: 001-11960

 **AstraZeneca PLC**

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 **AstraZeneca PLC**

INDEX TO EXHIBITS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

 ***1.***

 ***Result of AGM***

9 April 2026

 **Results of Annual General Meeting held on 9 April 2026**

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Resolution**<br>| **Votes for**<br>| **% of votes cast**<br>| **Votes against**<br>| **% of votes cast**<br>| **Votes cast in total**<br>| **Total votes cast as a % of issued share capital**<br>| **Votes withheld**<br>|
| **1**<br>| To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025<br>| 1198663815<br>| 99.99%<br>| 166701<br>| 0.01%<br>| 1198830516<br>| 77.29%<br>| 2309793<br>|
| **2**<br>| To confirm the 2025 interim dividends<br>| 1199596253<br>| 99.91%<br>| 1054621<br>| 0.09%<br>| 1200650874<br>| 77.41%<br>| 489438<br>|
| **3**<br>| To appoint KPMG LLP as Auditor<br>| 1200331533<br>| 99.98%<br>| 203239<br>| 0.02%<br>| 1200534772<br>| 77.40%<br>| 605649<br>|
| **4**<br>| To authorise the Directors to agree the remuneration of the Auditor<br>| 1200231237<br>| 99.98%<br>| 277426<br>| 0.02%<br>| 1200508663<br>| 77.40%<br>| 631646<br>|
| **5a**<br>| To re-elect Michel Demaré as a Director<br>| 1181183631<br>| 98.39%<br>| 19312258<br>| 1.61%<br>| 1200495889<br>| 77.40%<br>| 644420<br>|
| **5b**<br>| To re-elect Pascal Soriot as a Director<br>| 1188466505<br>| 99.00%<br>| 12056196<br>| 1.00%<br>| 1200522701<br>| 77.40%<br>| 617611<br>|
| **5c**<br>| To re-elect Aradhana Sarin as a Director<br>| 1191427943<br>| 99.30%<br>| 8391362<br>| 0.70%<br>| 1199819305<br>| 77.36%<br>| 1321004<br>|
| **5d**<br>| To re-elect Philip Broadley as a Director<br>| 1171470116<br>| 97.59%<br>| 28983447<br>| 2.41%<br>| 1200453563<br>| 77.40%<br>| 686746<br>|
| **5e**<br>| To re-elect Euan Ashley as a Director<br>| 1197441098<br>| 99.75%<br>| 3022489<br>| 0.25%<br>| 1200463587<br>| 77.40%<br>| 676722<br>|
| **5f**<br>| To re-elect Birgit Conix as a Director<br>| 1200028460<br>| 99.96%<br>| 428931<br>| 0.04%<br>| 1200457391<br>| 77.40%<br>| 683030<br>|
| **5g**<br>| To re-elect Rene Haas as a Director<br>| 1176085879<br>| 97.97%<br>| 24361879<br>| 2.03%<br>| 1200447758<br>| 77.40%<br>| 692663<br>|
| **5h**<br>| To re-elect Karen Knudsen as a Director<br>| 1200091469<br>| 99.97%<br>| 370843<br>| 0.03%<br>| 1200462312<br>| 77.40%<br>| 678109<br>|
| **5i**<br>| To re-elect Diana Layfield as a Director<br>| 1199711377<br>| 99.94%<br>| 755622<br>| 0.06%<br>| 1200466999<br>| 77.40%<br>| 673422<br>|
| **5j**<br>| To re-elect Anna Manz as a Director<br>| 1199171542<br>| 99.89%<br>| 1310287<br>| 0.11%<br>| 1200481829<br>| 77.40%<br>| 658592<br>|
| **5k**<br>| To re-elect Sheri McCoy as a Director<br>| 1181129650<br>| 98.39%<br>| 19334808<br>| 1.61%<br>| 1200464458<br>| 77.40%<br>| 675963<br>|
| **5l**<br>| To re-elect Tony Mok as a Director<br>| 1197756109<br>| 99.77%<br>| 2702422<br>| 0.23%<br>| 1200458531<br>| 77.40%<br>| 681890<br>|
| **5m**<br>| To re-elect Marcus Wallenberg as a Director<br>| 993713162<br>| 83.80%<br>| 192121282<br>| 16.20%<br>| 1185834444<br>| 76.46%<br>| 15305980<br>|
| **6**<br>| To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025<br>| 1161885452<br>| 96.78%<br>| 38608771<br>| 3.22%<br>| 1200494223<br>| 77.40%<br>| 646086<br>|
| **7**<br>| To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020<br>| 1186833063<br>| 98.89%<br>| 13376194<br>| 1.11%<br>| 1200209257<br>| 77.38%<br>| 930948<br>|
| **8**<br>| To authorise limited political donations<br>| 1176818096<br>| 98.50%<br>| 17954803<br>| 1.50%<br>| 1194772899<br>| 77.03%<br>| 6367525<br>|
| **9**<br>| To authorise the Directors to allot shares<br>| 1115450202<br>| 92.92%<br>| 84989076<br>| 7.08%<br>| 1200439278<br>| 77.40%<br>| 701146<br>|
| **10**<br>| To authorise the Directors to disapply pre-emption rights<br>| 1113184536<br>| 92.75%<br>| 87024695<br>| 7.25%<br>| 1200209231<br>| 77.38%<br>| 930073<br>|
| **11**<br>| To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments<br>| 1053612673<br>| 87.78%<br>| 146670037<br>| 12.22%<br>| 1200282710<br>| 77.39%<br>| 856594<br>|
| **12**<br>| To authorise the Company to purchase its own shares<br>| 1197748658<br>| 99.81%<br>| 2335330<br>| 0.19%<br>| 1200083988<br>| 77.38%<br>| 1056436<br>|
| **13**<br>| To reduce the notice period for general meetings<br>| 1108104727<br>| 92.31%<br>| 92307790<br>| 7.69%<br>| 1200412517<br>| 77.40%<br>| 727904<br>|

---

Nazneen Rahman retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, she will receive her pro-rata entitlement to non-executive director fees for the month of April 2026. No other remuneration payment or payment for loss of office will be made.

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at <u>https://data.fca.org.uk/#/nsm/nationalstoragemechanism</u>.

 **Issued capital**

As at 7 April 2026, the number of issued shares of the Company was 1,550,988,781 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 **AstraZeneca**

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit <u>astrazeneca.com</u> and follow the Company on social media <u>@AstraZeneca</u> 

 **Contacts**

For details on how to contact the Investor Relations Team, please click <u>here</u>. For Media contacts, click <u>here</u>.

 **Matthew Bowden**

 **Company Secretary**

 **AstraZeneca PLC**

<u>SIGNATURES</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 09 April 2026

---

| |
|:---|
| By: /s/ Matthew Bowden |
| Name: Matthew Bowden |
| Title: Company Secretary |

---

<br>